0001104659-24-060594.txt : 20240513
0001104659-24-060594.hdr.sgml : 20240513
20240513163243
ACCESSION NUMBER: 0001104659-24-060594
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240509
FILED AS OF DATE: 20240513
DATE AS OF CHANGE: 20240513
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Brenner Martin
CENTRAL INDEX KEY: 0001770235
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-35023
FILM NUMBER: 24939634
MAIL ADDRESS:
STREET 1: C/O PFENEX INC.
STREET 2: 10790 ROSELLE STREET
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: iBio, Inc.
CENTRAL INDEX KEY: 0001420720
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 262797813
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
BUSINESS PHONE: 302 355-0650
MAIL ADDRESS:
STREET 1: 600 MADISON AVENUE, SUITE 1601
CITY: NEW YORK
STATE: NY
ZIP: 10022-1737
FORMER COMPANY:
FORMER CONFORMED NAME: iBioPharma, Inc.
DATE OF NAME CHANGE: 20080806
FORMER COMPANY:
FORMER CONFORMED NAME: InB:Biotechnologies, Inc.
DATE OF NAME CHANGE: 20071210
4
1
tm2414241-2_4seq1.xml
OWNERSHIP DOCUMENT
X0508
4
2024-05-09
0
0001420720
iBio, Inc.
IBIO
0001770235
Brenner Martin
C/O IBIO, INC., 8800 HSC PARKWAY
BRYAN
TX
77807
0
1
0
0
See Remarks
0
Stock Option (right to buy)
1.88
2024-05-09
4
A
0
147300
0
A
2034-05-09
Common Stock
147300
147300
D
Stock Option (right to buy)
1.88
2024-05-09
4
A
0
110000
0
A
2034-05-09
Common Stock
110000
110000
D
These options vest as follows: 25% of the shares of common stock underlying the options granted will vest on the one-year anniversary of the grant date and after the one-year anniversary of the grant date, 6.25% of the shares of common stock underlying the options granted will vest for each additional three months of employment, provided that the reporting person remains employed by iBio, Inc.
These options vest in equal amounts on a quarterly basis over a 36-month period commencing on the date of grant.
Chief Executive Officer and Chief Scientific Officer
/s/ Martin Brenner
2024-05-13